Edition:
United States

Roche Holding AG (ROCZg.F)

ROCZg.F on Frankfurt Stock Exchange

230.79EUR
28 Jun 2017
Change (% chg)

€-1.17 (-0.51%)
Prev Close
€231.96
Open
€230.79
Day's High
€230.79
Day's Low
€230.79
Volume
18
Avg. Vol
5,737
52-wk High
€249.52
52-wk Low
€201.96

Latest Key Developments (Source: Significant Developments)

Epizyme expands clinical collaboration with Genentech
Monday, 26 Jun 2017 06:30am EDT 

June 26 (Reuters) - Epizyme Inc :Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc.Epizyme inc - expanded its clinical collaboration with genentech, a member of roche group.Epizyme inc - under new agreement, tazemetostat administered in combination with atezolizumab will be evaluated in a phase 1b/2 clinical study.Epizyme inc - financial terms are not disclosed and epizyme will retain global development and commercialization rights to tazemetostat..Epizyme inc - genentech will sponsor planned phase 1b/2 clinical trial, which is expected to be initiated by end of 2017.  Full Article

Roche says haemophilia drug emicizumab showed positive results
Monday, 26 Jun 2017 02:03am EDT 

June 26 (Reuters) - Roche Holding Ag :Says emicizumab showed positive results in phase iii studies (haven 1 and haven 2) in haemophilia a with inhibitors ahead of an industry meeting in July.  Full Article

Roche receives FDA approval for fourth-gen HIV combination antigen-antibody assay
Friday, 23 Jun 2017 09:20am EDT 

June 23 (Reuters) - Roche Holding Ag :Roche receives fda approval for fourth-generation hiv combination antigen-antibody assay --allowing detection of infection with high sensitivity and specificity.Roche diagnostics - elecsys hiv combi pt assay has received fda pma approval from u.s. Fda.  Full Article

Roche says Ocrevus reduced measures of MS progression
Friday, 23 Jun 2017 02:39am EDT 

June 23 (Reuters) - Roche Holding Ag :Says new data at ean show roche’s ocrevus (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis.  Full Article

Roche presents new data from study on Gazyva
Friday, 23 Jun 2017 02:37am EDT 

June 23 (Reuters) - Roche Holding Ag :Says roche presents new data from gallium study reinforcing clinical benefit of gazyva/gazyvaro in people with previously untreated follicular lymphoma.  Full Article

Roche says presentation confirms venclexta/venclyxto monotherapy benefit
Friday, 23 Jun 2017 02:37am EDT 

June 23 (Reuters) - Roche Holding Ag :Says presentation confirms venclexta/venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers.  Full Article

Genentech says FDA approves Rituxan Hycela for subcutaneous injection in certain blood cancers
Thursday, 22 Jun 2017 02:19pm EDT 

June 22 (Reuters) - Genentech : :FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers.Genentech - Rituxan Hycela will be available to people in United States within one to two weeks, and intravenous Rituxan will continue to be available.  Full Article

Aspen Pharmacare says not yet had any engagement with commission on matters raised
Wednesday, 14 Jun 2017 05:11am EDT 

June 14 (Reuters) - Aspen Pharmacare Holdings Ltd :‍To date, not had any engagement with commission on matters contained in commission's announcement of 13 June 2017​.  Full Article

Aspen Pharmacare responds to South African Competition Commission investigation announcement
Tuesday, 13 Jun 2017 09:00am EDT 

June 13 (Reuters) - Aspen Pharmacare Holdings Ltd :Noted announcement by South African Competition Commission.Announcement that SACC will be investigating co for suspected abuse of dominance in respect of provision of cancer medication in South Africa.‍Committed to full and constructive engagement with Competition Commission in this investigation.Not increased pricing of its products outside of this regulatory framework.Clearly demonstrated its commitment to providing quality medicines affordably over many years; Supply of oncology products in question is no exception​​​​.  Full Article

Roche Holding Ltd reports a 23.62 percent stake in Senseonics Holdings
Friday, 9 Jun 2017 08:40am EDT 

June 9 (Reuters) - Roche Holding Ag :Roche Holding Ltd reports a 23.62 percent stake in Senseonics Holdings Inc as of June 1, 2017 - SEC filing.  Full Article

More From Around the Web

Photo

New form of Roche's Esbriet approved in Europe for lung disorder

ZURICH Roche said a new Esbriet tablet formulation was approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF), a fatal condition that causes irreversible, progressive scarring of the lungs.